NIKKEI 225
33,195.54 -235.97 (-0.71%) HANG SENG
16,749.12 -81.18 (-0.48%) CRUDE OIL
73.48 -0.59 (-0.80%) GOLD FUTURES
2,105.60 +15.90 (+0.76%) DOW
36,245.50 +294.60 (+0.82%) Bitcoin GBP
32,645.07 +1,549.11 (+4.98%)
Lonza Group Ltd (0QNO.IL)
| Previous close | 402.20 |
| Open | 401.50 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 396.40 - 404.10 |
| 52-week range | 396.40 - 767.40 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireVertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes (T1D) Cell Therapies
BOSTON & BASEL, Switzerland, June 26, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Lonza (SIX: LONN) today announced a strategic collaboration to support the manufacture of Vertex’s portfolio of investigational stem cell-derived, fully differentiated insulin-producing islet cell therapies for people with T1D, currently focusing on the VX-880 and VX-264 programs that are currently in clinical trials.
Globe NewswireSimris Alg ab Signs Partnership Agreement With Lonza Ltd to Promote Its Adc Payload Technology
Strategic collaboration agreement to commercialize Simris’ novel Antibody-Drug Conjugate (ADC) payload platformSimris grants Lonza, as its Contract Development & Manufacturing Organization (CDMO) partner, the global exclusive rights to offer its ADC technology to biopharmaceutical companiesSimris will promote Lonza as its exclusive CDMO partner to customers interested in licensing its technology Stockholm, Sweden, March 06, 2023 (GLOBE NEWSWIRE) -- Simris Alg AB (publ), a European biologics comp
